Mitochondrially-targetted Cyclosporin-A for the Treatment of Heart Attacks & Stroke
We have developed a novel pharmaceutical composition that dramatically reduces tissue damage following heart attacks or stroke. Our patented position specifically targets a previously off-patent pharmaceutical to give a cytoprotective effect. We are currently in early pre-clinical testing, and we welcome negotiations with potential exclusive licensees.
| Date added | 07 Dec 2009 |
|---|---|
| Reference number | 38-020 (Compound reference: UCLB38020). |
| Status | Patent application pending |
| Availability | Available for exclusive licensing |
| References | Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation; Malouitre S, Dube H, Selwood D, Crompton M. Biochem J. 2009 Oct 15. Link to recent Biochem J pape |
The technology and its advantages
Cyclosporin-A is a well-known, off-patent pharmaceutical that previously achieved billion-plus annual sales. We have engineered CsA to specifically target Cyclophilin D, reducing tissue damage caused by heart attacks, strokes, and other conditions.
Our data show inhibition of mitochondrial Cyclophilin D significantly reduces ischaemia-reperfusion injury following heart attack or stroke. We have patented a portfolio of methods to target CsA to mitochondria, and we have flexibility to alter solubility and other factors of the medicament.
Market opportunity
Cyclosporin-A is a pharmaceutical composition that achieved multi-billion dollar sales, and an exemplary safety record, before going off-patent.
Ischaemia-reperfusion injury causes significant tissue damage following heart attacks, strokes, and other incidents. The aging population is causing an increase in the health economic cost of such incidents.
By re-engineering a known pharmaceutical, we believe we have slightly de-risked the developed of this medicament.
Further information
Please contact Chris Loryman, UCL Business PLC
T +44 (0)20 7679 9000
E c.loryman@uclb.com
